Envista (NVST)
(Delayed Data from NYSE)
$16.50 USD
+1.20 (7.84%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $16.52 +0.02 (0.12%) 7:58 PM ET
5-Strong Sell of 5 5
C Value C Growth C Momentum B VGM
Envista (NVST) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$18.59 | $23.00 | $16.00 | 21.50% |
Price Target
Based on short-term price targets offered by 11 analysts, the average price target for Envista comes to $18.59. The forecasts range from a low of $16.00 to a high of $23.00. The average price target represents an increase of 21.5% from the last closing price of $15.30.
Analyst Price Targets (11)
Broker Rating
Envista currently has an average brokerage recommendation (ABR) of 2.69 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 13 brokerage firms. The current ABR compares to an ABR of 2.69 a month ago based on 13 recommendations.
Of the 13 recommendations deriving the current ABR, four are Strong Buy, representing 30.77% of all recommendations. A month ago, Strong Buy represented 30.77%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/NVST.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 4 | 4 | 3 | 3 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 8 | 7 | 7 | 7 | 7 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 2 | 2 | 2 | 2 | 2 |
ABR | 2.85 | 2.69 | 2.69 | 2.83 | 2.83 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/8/2024 | Needham & Company | David Saxon | Hold | Hold |
8/8/2024 | William Blair | Brandon Vazquez | Hold | Hold |
8/8/2024 | SVB Securities | Michael Cherny | Strong Sell | Strong Sell |
7/30/2024 | Piper Sandler | Jason Bednar | Hold | Hold |
6/25/2024 | Evercore Partners | Elizabeth Anderson | Not Available | Strong Buy |
5/2/2024 | Robert W. Baird & Co. | Jeffrey D Johnson | Hold | Hold |
5/2/2024 | Goldman Sachs | Nathan Rich | Strong Sell | Strong Sell |
1/5/2024 | UBS | Kevin Caliendo | Not Available | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.85 |
ABR (Last week) | 2.69 |
# of Recs in ABR | 13 |
Average Target Price | $18.23 |
LT Growth Rate | 1.00% |
Industry | Medical - Products |
Industry Rank by ABR | 90 of 253 |
Current Quarter EPS Est: | 0.27 |